Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study

BACKGROUND: TNF inhibitors have been used as a treatment for moderate to severe RA patients. However, reliable biomarkers that predict therapeutic response to TNF inhibitors are lacking. In this study, we investigated whether chemokines may represent useful biomarkers to predict the response to TNF...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Bobby Kwanghoon, Kuzin, Igor, Gaughan, John P., Olsen, Nancy J., Bottaro, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840903/
https://www.ncbi.nlm.nih.gov/pubmed/27102921
http://dx.doi.org/10.1186/s13075-016-0995-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840903/
https://www.ncbi.nlm.nih.gov/pubmed/27102921
http://dx.doi.org/10.1186/s13075-016-0995-0

Ejemplares similares